Allogene Therapeutics, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.allogene.com

Moat Score

Market Cap $430.72M
PE -0
Debt $NaN
Cash $61.53M
EV $NaN
FCF -$217.93M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$1.52B
EBIT	-$297.88M
ROE	-328%
ROA	-51%
FCF	-$217.93M
Equity	$463.75M
Growth Stability	1
PE	-0.28
PB	0.93
P/FCF	-1.98
P/S	-19.58K
Price/Cash	0.14
Net Margins	-898K%
Op. Margins	1M%
Sales Growth YoY	-100%
Sales CAGR	-45%
Equity CAGR	-7%
Earnings Growth YoY	8%

Earnings Growth QoQ	-0%
Sales CAGR 5Y	-87%
Equity CAGR 5Y	-14%
Earnings CAGR 3Y	-81%
Sales CAGR 3Y	-81%
Equity CAGR 3Y	-22%
Market Cap	$430.72M
Revenue	-$22.00K
Assets	$589.12M
Cash	$61.53M
Shares Outstanding	189.52M
Moat Score	0%
Working Capital	271.84M
Current Ratio	9.35
Shares Growth 3y	11%
Equity Growth QoQ	-10%
Equity Growth YoY	-20%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

SEC Filings

Direct access to Allogene Therapeutics, Inc. (ALLO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Allogene Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Allogene Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Allogene Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Allogene Therapeutics, Inc..

Years

Calculation mode

= -$2.2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$218M	-$218M	-$218M	-$218M	-$218M	-$218M	-$218M	-$218M	-$218M	-$218M	-$218M	-$2.2B
DCF		-$198M	-$180M	-$164M	-$149M	-$135M	-$123M	-$112M	-$102M	-$92M	-$84M	-$840M
Value	-$2.2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-2K%	-509K%	-2M%	-898K%
ROA	-	-25%	-26%	-20%	-25%	-41%	-51%	-51%
ROE	-	-30%	-63%	-60%	-99%	-186%	-305%	-328%

Bad Net Margins (-898.41K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-99%	-61%	-87%
Earnings YoY growth	-	11M%	87%	63%	40%	37%	26%	-
Equity YoY growth	-	-35M%	-11%	72%	-15%	-27%	-23%	-14%
FCF YoY growth	-	-	293%	-4%	14%	9%	6%	-